Search

Your search keyword '"Gebel, J."' showing total 276 results
Start Over Author "Gebel, J."
Sorry, I don't understand your search. ×
276 results on '"Gebel, J."'

8. Efficacy of five ‘sporicidal’ surface disinfectants against Clostridioides difficile spores in suspension tests and 4-field tests

Author

Gemein, S., primary, Andrich, R., additional, Christiansen, B., additional, Decius, M., additional, Exner, M., additional, Hunsinger, B., additional, Imenova, E., additional, Kampf, G., additional, Koburger-Janssen, T., additional, Konrat, K., additional, Martiny, H., additional, Meckel, M., additional, Mutters, N.T., additional, Pitten, F-A., additional, Schulz, S., additional, Schwebke, I., additional, and Gebel, J., additional

Published
2022
Full Text
View/download PDF

11. Reply to the letter to the editor by R. Papke

Author

Exner, M, Bhattacharya, S, Gebel, J, Goroncy-Bermes, P, Hartemann, P, Heeg, P, Ilschner, C, Kramer, A, Ling, ML, Merkens, W, Oltmanns, P, Pitten, F, Rotter, M, Schmithausen, RM, Sonntag, HG, Steinhauer, K, and Trautmann, M

Subjects
ddc: 610, Medicine, 610 Medical sciences, Public aspects of medicine, RA1-1270, Microbiology, QR1-502, Article
Abstract

[for full text, please go to the a.m. URL], GMS Hygiene and Infection Control; 16:Doc23

Published
2021

13. Elution von Instrumentierkanälen mittels Flush-Brush-Flush-Verfahren zur hygienisch-mikrobiologischen Überprüfung aufbereiteter Endoskope.

Author

Wehrl, M., Barone, P., Biering, H., Brill, F. H. H., Dabrowski, M., Diedrich, D., Gebel, J., Gemein, S., Geyer., D., Halvarsson, A., Hücker, B., Kampe, A., Kampf, B., Kruse, K., Lenz, J., Martiny, H., Orschel, U., Plevschinski, M., Riebe, O., and Roth, K.

Subjects
FIELD research, SALT, MEDICAL equipment contamination, WATER, ENDOSCOPES, MICROBIOLOGICAL techniques, DESCRIPTIVE statistics, STERILIZATION (Disinfection), GLYCERIN, COLLECTION & preservation of biological specimens, MEDICAL equipment reuse, PREVENTION
Published
2022

15. Test methods for surface disinfection: comparison of the Wiperator ASTM standard E2967-15 and the 4-field test EN 16615

Author

Jacobshagen, A, Gemein, S, Exner, M, and Gebel, J

Subjects
lcsh:Public aspects of medicine, lcsh:R, lcsh:QR1-502, lcsh:Medicine, lcsh:RA1-1270, 010501 environmental sciences, 610 Medical sciences, Medicine, 01 natural sciences, Article, lcsh:Microbiology, Flächendesinfektion, disinfectant wipe, 03 medical and health sciences, Desinfektionstuch, 0302 clinical medicine, ddc: 610, surface disinfection, 4-Felder Test, 030212 general & internal medicine, wiperator, 0105 earth and related environmental sciences, 4-field test
Abstract

Aim: Two test methods for surface disinfection (phase 2, step 2) – the Wiperator method (ASTM standard E2967-15) and the 4-field test (EN 16615) – were compared using a disinfectant solution based on quaternary ammonium compounds and a ready-to-use alcohol-based wipe. As test organisms, Staphylococcusaureus and Pseudomonasaeruginosa were used. Results: While the 4-field test is a manual method and better reflects the process in practice, with the Wiperator, the wiping process is better controlled because it is an automated procedure. A comparison of the effects of both methods on the target log10-reduction of S. aureus and P. aeruginosa indicates a statistically significant difference between the two test methods (Mann-Whitney U-Test. S. aureus: 0 (Umin), Ziel: Zwei praxisnahe Testmethoden (Phase 2, Stufe 2) für die Flächendesinfektion – die Wiperator-Methode (ASTM-Standard E2967-15) und der 4-Felder-Test (EN 16615) – wurden verglichen. Als Prüfprodukte wurden eine Desinfektionslösung auf Basis von quartären Ammoniumverbindungen und ein gebrauchsfertiges Desinfektionstuch auf Basis von Alkoholen verwendet. Ergebnisse: Während es sich beim 4-Felder-Test um eine manuelle Methode handelt, die die Praxis besser widerspiegelt, ist die Wiperator-Methode ein maschinelles Verfahren mit einem kontrollierteren Wischvorgang. Im Vergleich der Wirkungen beider Verfahren auf die Zielgröße log10-Reduktion von S. aureus und P. aeruginosa anhand zweier unabhängiger Stichproben ergab sich zwischen beiden Testverfahren ein statistisch signifikanter Unterschied (Mann-Whitney U-Test: S. aureus: 0 (Umin), GMS Hygiene and Infection Control; 15:Doc04

Published
2020

16. Discovery of Protein-Protein Interaction Inhibitors by Integrating Protein Engineering and Chemical Screening Platforms

Author

Maculins, T., Garcia-Pardo, J., Skenderovic, A., Gebel, J., Putyrski, M., Vorobyov, A., Busse, P., Varga, G., Kuzikov, M., Zaliani, A., Rahighi, S., Schaeffer, V., Parnham, M.J., Sidhu, S.S., Ernst, A., Dötsch, V., Akutsu, M., Dikic, I., and Publica

Abstract

Protein-protein interactions (PPIs) govern intracellular life, and identification of PPI inhibitors is challenging. Roadblocks in assay development stemming from weak binding affinities of natural PPIs impede progress in this field. We postulated that enhancing binding affinity of natural PPIs via protein engineering will aid assay development and hit discovery. This proof-of-principle study targets PPI between linear ubiquitin chains and NEMO UBAN domain, which activates NF-kB signaling. Using phage display, we generated ubiquitin variants that bind to the functional UBAN epitope with high affinity, act as competitive inhibitors, and structurally maintain the existing PPI interface. When utilized in assay development, variants enable generation of robust cell-based assays for chemical screening. Top compounds identified using this approach directly bind to UBAN and dampen NF-kB signaling. This study illustrates advantages of integrating protein engineering and chemical screening in hit identification, a development that we anticipate will have wide application in drug discovery.

Published
2020

19. Microbial load of drinking water reservoir tributaries during extreme rainfall and runoff

Author

Kistemann, T., Clasen, T., Koch, C., Dangendorf, F., Fischeder, R., Gebel, J., Vacata, V., and Exner, M.

Subjects
Water -- Bacteriology, Drinking water -- Contamination, Rain and rainfall -- Environmental aspects, Biological sciences
Abstract

Researchers have confirmed that the increased turbidity seen in mountain creeks after a heavy rainfall or snowmelt is caused by increased amounts of bacteria in the water. This includes increased levels of E. coli and other coliforms, fecal streptococci, and Clostridium perfringens. Raw water surveillance programs should sample water during periods of heavy runoff, since many rivers flow into reservoirs that provide drinking water.

Published
2002

30. Interlaboratory reproducibility of a test method following 4-field test methodology to evaluate the susceptibility of Clostridium difficile spores

Author

Gemein, S., primary, Gebel, J., additional, Christiansen, B., additional, Martiny, H., additional, Vossebein, L., additional, Brill, F.H.H., additional, Decius, M., additional, Eggers, M., additional, Koburger-Janssen, T., additional, Meckel, M., additional, Werner, S., additional, Hunsinger, B., additional, Selhorst, T., additional, Kampf, G., additional, and Exner, M., additional

Published
2019
Full Text
View/download PDF

38. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

Author

Nicholls, Stephen J., Kastelein, John J. P., Schwartz, Gregory G., Bash, Dianna, Rosenson, Robert S., Cavender, Matthew A., Brennan, Danielle M., Koenig, Wolfgang, Jukema, J. Wouter, Nambi, Vijay, Wright, R. Scott, Menon, Venu, Lincoff, A. Michael, Nissen, Hennekens C, Steven E., Brown, Wv, Demets, D, Pfeffer, M, Roleau, J, Abraham, J, Gebel, J, Huff, C, Katzan, I, Shishehbor, M, Rassi, A, Uchino, K, Vest, A, Zishiri, E, Heckman, Mj, Balog, C, Dart, A, Amerena, J, Prasad, C, Farshid, A, Gunalingam, B, Thompson, P, Collins, N, Arstall, M, van Gaal, W, Aroney, C, Mahar, L, Youssef, G, Horowitz, J, Anand, D, Rodes-Cabau, J, Polasek, P, Lai, C, Huynh, T, Hubacek, J, Kokis, A, Paradis, Jm, Mukherjee, A, Senaratne, M, Constance, C, Gosselin, G, Lavi, S, Parker, J, Zadra, R, Abramson, B, Della-Siega, A, Spinar, J, Pudil, R, Motovska, Z, Maly, M, Hutyra, M, Pleva, L, Mayer, O, Semenka, J, Klimovic, T, Horak, D, Cervinka, P, Klimsa, Z, Hulinsky, V, Reichert, P, Monhart, Z, Rotterova, H, Kobulia, B, Shaburishvili, T, Mamatsashvili, M, Chapidze, G, Chumburidze, V, Megreladze, I, Khintibidze, I, Leithäuser, B, Voehringer, Hf, Wachter, R, Nogai, K, Lapp, H, Haltern, G, Gielen, S, Dorsel, T, Möllmann, H, Stellbrink, C, Hengstenberg, C, Dengler, T, Heuer, H, Kreuzer, J, Leschke, M, Mudra, H, Werner, N, Braun-Dullaeus, R, Rosenberg, M, Frey, N, Koenig, W, Strasser, R, Genth-Zotz, S, Kiss, R, Nagy, A, Kovacs, Z, Csapo, K, Edes, I, Sereg, M, Vertes, A, Ronaszeki, A, Kancz, S, Benczur, B, Polgar, P, Muller, G, Simonyi, G, Dezsi, C, Merkely, B, Dinnyes, J, Lupkovics, G, Kahali, D, Banker, D, Trivedi, S, Rajput, R, Premchand, R, Dani, S, Vadaganelli, P, Gupta, S, Chandra, S, Fulwani, M, Chawla, K, Parikh, K, Prati, F, Speciale, G, Valgimigli, M, Suriano, P, Sangiorgi, G, Fineschi, M, Merenda, R, Marenzi, G, Berti, S, Corrada, E, Cuccia, C, Testa, R, Moretti, L, Mennuni, M, Biasucci, Lm, Lioy, E, Auguadro, C, Magagnini, E, Fedele, F, Piscione, F, Azar, R, Trip, Md, Liem, A, den Hartoog, M, Lenderink, T, van de Wetering ML, Lok, D, Oei, F, Tans, Jg, Ilmer, B, Keijzers, M, Monraats, P, Kedhi, E, Breedveld, Rw, Herrman, J, van Wijk, L, Ronner, E, Nierop, P, Bosschaert, M, Hermans, W, Doevendans, P, Troquay, R, van der Heijden, R, Veen, G, Bokern, Mj, Bronzwaer, Pn, Kie, Sh, Den Hartog, F, Elliott, J, Wilkins, G, Hart, H, Devlin, G, Harding, S, Ponikowski, P, Madej, A, Kochmanski, M, Witkowski, A, Pluta, W, Bronisz, M, Kornacewicz-Jach, Z, Wysokinski, A, Ujda, M, Drozdz, J, Derlaga, B, Gessek, J, Dabrowski, M, Miekus, P, Kozlowski, A, Gniot, J, Musial, W, Dobrzycki, S, Rynkiewicz, A, Psuja, P, Rekosz, J, Drzewiecki, A, Kuznetsov, V, Gordeev, I, Goloshchekin, B, Markov, V, Barbarich, V, Belenky, D, Mikhin, V, Volkova, E, Timofeev, A, Ermoshkina, L, Barbarash, O, Klein, G, Libis, R, Vishnevsky, A, Linev, K, Khaisheva, L, Ruda, M, Dovgalevskiy, Y, Shvarts, Y, Zateyshchikov, D, Kostenko, V, Shalnev, V, Simanenkov, V, Arkhipov, M, Ovcharenko, E, Guseva, G, Akhunova, S, Ortiz, Ai, Navarro, Mj, Romero, Aj, Goya, Il, Peñaranda, As, Cendon, Aa, Rubio, Am, Zubiri, Jj, Soriano, Fr, Sanz, Rr, Genís, Ab, Lago, Vn, Fernández, Jd, Romo, Ai, Franco, Sn, Martin, Ih, Montero, Js, Martin Mde, M, González, Mj, Antolin, Jm, Areses, El, Miranda, Jm, Alonso-Pulpón, L, Esquivias, Gb, Jarne, Ef, Cortés, Jm, Pérez, Mb, Gormaz, Cl, Alegret, Jm, Nava, Js, Ingelmo, Jm, Urbano, Rh, Sanmartín, M, Katerenchuk, O, Vakaliuk, I, Karpenko, O, Prokhorov, O, Koval, O, Faynyk, A, Kopytsya, M, Karpenko, Y, Kraiz, I, Feskov, O, Rudenko, L, Kozhukhov, S, Goloborodko, B, Rivera, E, Broadwater, S, Crowley, S, Vijay, N, Goswami, R, Ferrier, L, Blanchard, A, Mccullum, K, Chernick, R, Bertolet, B, Battaglia, J, Richardson, J, Lochridge, S, Lieberman, S, Amkieh, A, Cavender, Jb, Denning, S, Treasure, C, Kmetzo, J, Stillabower, M, Brilakis, E, Schwartz, G, Acheatel, R, Kukuy, E, Ashchi, M, Skelding, K, Martin, L, Gillespie, E, French, W, Pollock, S, Polk, D, Black, R, Drenning, D, Anderson, J, Sanz, M, Korban, E, Wiley, M, Rezkalla, S, Minisi, A, Shah, A, Silverman, P, Amlani, M, Eaton, G, Brown, A, Jay, D, Loussararian, A, Lamas, G, Lauer, M, Williams, J, Asfour, A, Runquist, L, Robertson, R, Blonder, R, Davies, C, Downes, T, Chronos, N, Marso, S, Haldis, T, Eich, D, Ahmed, M, East, C, Macdonald, L, Seigel, P, White, M, Camp, A, Kleiman, N, Burtt, D, Strain, J, Go, B, Henry, P, Sultan, P, Delafontaine, P, Kashou, H, Lambert, C, Movahed, M, Saucedo, J, Thadani, U, Chandrashekhar, Y, Lu, D, Chandna, H, Mann, J, Ramaswamy, G, Browne, K, Janik, M, Cannon, K, Tolerico, P., Berni, Andrea, ACS - Amsterdam Cardiovascular Sciences, Vascular Medicine, and Cardiology

Subjects
Male, Indoles, Acetates, Acute Coronary Syndrome, Aged, Angina, Unstable, Atherosclerosis, Double-Blind Method, Early Termination of Clinical Trials, Female, Heptanoic Acids, Humans, Middle Aged, Phospholipases A, Phospholipases A2, Secretory, Pyrroles, Risk, Stroke, Survival Analysis, Treatment Outcome, Myocardial Infarction, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Atorvastatin, Clinical endpoint, Medicine (all), General Medicine, Angina, Keto Acids, medicine.medical_specialty, Acute coronary syndrome, Placebo, Unstable, Internal medicine, Multicenter trial, medicine, Atorvastatin Calcium, Unstable angina, business.industry, Secretory, medicine.disease, Interim analysis, Surgery, Phospholipases A2, chemistry, Varespladib, business
Abstract

Importance Secretory phospholipase A 2 (sPLA 2 ) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA 2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. Objective To determine the effects of sPLA 2 inhibition with varespladib on cardiovascular outcomes. Design, Setting, and Participants A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). Interventions Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. Main Outcomes and Measures The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. Results At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95% CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). Conclusions and Relevance In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA 2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. Trial Registration clinicaltrials.gov Identifier:NCT01130246

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results